Answers are grounded in this paper and cite their sources.
To the Editor: It may be years before populations that are most vulnerable to hepatitis E infection can benefit from the vaccine described by Zhang et al. (March 5 issue).1 With no effective treatment and little evidence of effective control measures,2 public health practitioners and clinicians are often left powerless while the most vulnerable patients (especially pregnant women) die. Outbreaks of hepatitis E during complex emergencies in Africa have been both large and protracted.3,4 Reactive vaccination may be the most promising tool for attacking such epidemics, especially if a shortened regimen with one or two doses is as effective as clinical data suggest.5 A number of challenges hinder the use of such a vaccine in mass campaigns during outbreaks; these include the bulky packaging, cold-chain requirements, and (most important) the lack of prequalification by the World Health Organization (WHO) (http://apps.who.int/prequal). WHO prequalification would reassure governments and allow international agencies to use the hepatitis E vaccine in settings where it is most needed. We encourage the global health community, including industry, to spare no efforts in making this vaccine a lifesaving reality for the most vulnerable populations. Andrew S. Azman, Ph.D.
No takes yet. Share an insight, caveat, or question.
Azman et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: